← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV24행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 1
allogenic NK cells (allogenic NK cells)
Fate Therapeutics·Acute Myeloid Leukemia
0%
Overview
Program
allogenic NK cells
Overview
Company
Fate Therapeutics
Overview
Modality
CGT
Overview
Target
Acute Myeloid Leukemia
Overview
Indication
Acute Myeloid Leukemia
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
MoA
Mechanism
targeting SUMOylation activates a noncanonical IFN-I pathway
MoA
Biomarker
biomarker of disease biology
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
PD
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia.. NK cells can play a significant role in the antitumoral immune response. In patients with acute myeloid leukemia (AML), NK cells are, however, often found in low numbers and exhibit poor activity, contributing to leukemic progression. Allogenic NK cell…
Toxicology
CRS
Reported
Clinical
Primary efficacy
0%
Clinical
ORR
0%
Clinical
PFS
1.14
Clinical
OS
2.66
Clinical
Result source
ClinicalTrials.gov NCT04582864
Clinical
Data Tier / Score
A · 36
Clinical
Program phase
PHASE_1
Clinical
Clinical sync
2026년 7월 18일 (8일 전)